Genetic Mutations Transform Low-Risk Childhood Cancers Into Fatal Tumors

Scientists have discovered that certain rhabdomyosarcoma tumors traditionally classified as low-risk actually harbor hidden populations of highly aggressive cancer cells, a finding published in Cancer Research that could reshape pediatric cancer treatment strategies.

Uncovering Hidden Aggressive Cells in Rhabdomyosarcoma

Rhabdomyosarcoma is an aggressive soft tissue cancer that develops from muscle tissue, standing as one of the most frequent soft tissue malignancies in children under 15 years old, with approximately 55 diagnoses annually in the United Kingdom, according to Children with Cancer UK. Unlike adult cancers that stem from years of aging or environmental exposures, childhood cancers typically arise from genetic alterations occurring during early development.

Traditionally, clinicians divide rhabdomyosarcoma into two distinct categories based on a specific genetic warning sign. This marker forms when two normally separate genes fuse together, creating an abnormal combination tied to severe disease. Children carrying this fusion marker face substantially lower survival rates than those without it, even under intensive treatment protocols, as outlined in a 2013 report in Pediatric Blood & Cancer by S. X. Skapek and colleagues.

Yet this classification system carries a critical blind spot. Some young patients whose tumors lack this high-risk fusion marker still develop fast-moving, fatal cancers. To decode this mystery, researchers from the Wellcome Sanger Institute, the University of Cambridge, Great Ormond Street Hospital (GOSH), University College London, and partner institutions examined tumor samples from 16 children.

Advanced Single-Cell Sequencing Reveals Shared Biological Pathways

Deploying advanced genetic analysis, the team investigated the tumor samples far beyond the limits of conventional techniques. They utilized single-cell RNA sequencing to measure gene activity within individual cells, mapping distinct cell populations that standard mass analysis overlooks. Spatial transcriptomics allowed scientists to map gene activity to precise physical locations inside the tissue, revealing exactly where aggressive cells concentrated.

The results demonstrated striking biological overlap between tumors previously sorted into separate risk categories. Certain non-high-risk cancers harbored cells displaying gene activity patterns nearly identical to those found in high-risk tumors. Crucially, these aggressive cells reached this dangerous state through different genetic mutations rather than a single shared abnormality, converging on the exact same cellular pathways.

By studying tumors one cell at a time, we uncovered hidden populations of aggressive cancer cells that conventional methods miss, said Dr. Karin Straathof, co-senior author at UCL Cancer Institute and GOSH. Although these tumors carry different genetic changes, many converge on the same aggressive pathways. This helps explain why some children who appear to have lower-risk disease can still have a devastating outcome.

Dr. Karin Straathof, UCL Cancer Institute and GOSH

Toward More Precise Pediatric Cancer Therapies

These findings lay the groundwork for transforming how clinicians diagnose and treat childhood malignancies. By detecting the biological signatures of aggressive cells at the time of diagnosis, doctors might accurately identify patients facing high relapse risks regardless of standard genetic test results. Such precision could spare lower-risk children from the harsh side effects of intense chemotherapy while routing high-risk patients to targeted therapies sooner.

Future treatment directions could include immunotherapy approaches such as CAR-T cell therapy, which uses engineered immune cells to target cancer cells while sparing healthy tissue, though such treatments require rigorous development for rhabdomyosarcoma.

Every child with cancer deserves the best possible chance of survival, said Sara Wakeling, Chief Executive Officer and co-founder of Alice’s Arc. We’re proud to support research into rhabdomyosarcoma, showing how cutting-edge technologies can uncover the biology driving aggressive childhood cancers. These discoveries bring us closer to more personalized treatments and better outcomes for children.

Sara Wakeling, Alice’s Arc

The study received support via a Cancer Research UK and Children with Cancer UK Innovation Award, alongside co-funding from Alice’s Arc and Wellcome. The findings suggest clinical practice may soon shift away from relying on a single genetic marker toward evaluating the broader biological state of the tumor.

Discovery research like this is essential to understand the unique biology of these cancers, said Dr. Laura Danielson, Children’s and Young Person’s Lead at Cancer Research UK. This important study demonstrates that aggressive tumors may share similar features, even if they carry different genetic changes. By helping researchers understand what these high-risk cancers have in common, this work adds a vital piece to the puzzle and could help guide future efforts to improve treatment for children and young people with rhabdomyosarcoma.

Dr. Laura Danielson, Cancer Research UK

By exposing aggressive behavior hidden beneath reassuring genetic categories, the research offers a path toward accurate risk stratification.

This work changes how we think about rhabdomyosarcoma, said Professor Sam Behjati, co-senior author formerly at the Wellcome Sanger Institute and Head of the Department of Paediatrics at the University of Cambridge. Rather than a single, abnormal gene, we’ve shown that there is an overarching cell state of aggressive disease that defies conventional classification systems. Understanding this shared biology could help identify children who need more intense treatment to improve their survival.

Professor Sam Behjati, University of Cambridge